Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

doi:10.1001/jama.289.16.2094

Skip navigation

Results
This Paper

To show you the PDF, we need your affiliation

(Don't worry, you'll only have to do this once)

Affiliation:

Cancel

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Trey T Sunderland, Gary G Linker, Nadeem N Mirza, Karen T KT Putnam, David L DL Friedman, Lida H LH Kimmel, Judy J Bergeson, Guy J GJ Manetti, Matthew M Zimmermann, Brian B Tang, John J JJ Bartko and Robert M RM Cohen JAMA 289(16):2094-103 (2003) PMID 12709467

Alzheimer disease (AD) is characterized by pathological results at autopsy of amyloid plaques and tau-associated neurofibrillary tangles, but the clinical diagnosis of AD is determined on the basis of medical history, cognitive symptoms, and exclusionary criteria. The search for antemortem biomarkers is intense and has focused on cerebrospinal fluid (CSF) beta-amyloid1-42 and tau proteins.

DOI: 10.1001/jama.289.16.2094
Version: za2963e q8za0 q8zb3 q8zc9 q8zdb q8zea q8zf8 q8zgc